Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective gastrointestinal decontamination before PEG to reduce sepsis
IRCT20181028041484N3Phase 3Recruiting
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Jan 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of vancomycin, colistin and amphotericin b in sepsis (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoint: Positive blood culture. Started Jan 2025; status: recruiting.
02
Drugs
vancomycincolistinamphotericin b
03
Conditions
sepsis
Beyond the preview
Go deeper on IRCT20181028041484N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181028041484N3.